Fundz

Brenus secures €11M to advance colorectal cancer vaccine development in a Series A extension, increasing total funding to €33.2M. The investment includes participation from existing and new investors.

PRIVATEJul 21, 2026

Amount Raised

€11 Million

Round Type

Series A

LyonBiotechnologyHealth CareTherapeutics

Investors

Korea Omega Investment CorpSambrinvestBio JagOrsaNoshaqCrédit AgricoleUI InvestissementAngelor

Description

Brenus, a Lyon-based biotech, has added €11M in extension funding to its Series A round, bringing the total for this round to €33.2M. This round aims to propel the development of STC-1010, its lead therapeutic cancer vaccine. Notable participants in this funding include existing investors and new entrants like Sambrinvest and Korea Omega Investment Corp. The company has raised a total of €38 million since its inception.

Who to call at Brenus, and when

A new round usually means Brenus is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day Brenus raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Brenus, from your own LinkedIn network
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Brenus

Location

Lyon, Auvergne Rhône Alpes, France

About

Brenus is a Lyon-based biotech company focused on developing immunotherapy treatments for microsatellite-stable metastatic colorectal cancer (MSS mCRC). Its lead candidate, STC-1010, is an off-the-shelf cancer vaccine made from established colorectal cancer cell lines. The company aims to create a more effective immune response against colorectal tumors, which are often resistant to traditional therapies. Since its inception, Brenus has raised a total of €38 million to support its innovative approach.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Brenus raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Predictive Intelligence
Strategic

ML-powered predictions for Brenus's next move

See what Strategic adds

Funding Insights

What this usually means
Typical timeline to Series B
Series A companies typically raise their next round in 10-18 months

Brenus raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.